Unicycive Therapeutics to Present Kidney Pipeline at Investment Conference
New York, Wednesday, 2 September 2026.
Unicycive Therapeutics will present its kidney disease drug pipeline, including an FDA-designated orphan drug, at the H.C. Wainwright conference on September 15, 2026.
Conference Presentation Announcement
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) announced on September 1, 2026, that its management team will present at the H.C. Wainwright 28th Annual Global Investment Conference [1][2][4]. The Los Altos, CA-based clinical-stage biotechnology company confirmed that Chief Executive Officer Shalabh Gupta, M.D., will deliver the presentation [1][4]. This upcoming appearance aims to update institutional investors on the company’s clinical pipeline and corporate growth milestones [1][2]. The announcement was disseminated via Globe Newswire and picked up by multiple financial news outlets on September 1, 2026 [2][4].
Clinical Pipeline and Regulatory Status
Unicycive Therapeutics focuses on developing novel treatments for patients suffering from kidney disease [1][2]. The company’s pipeline includes oxylanthanum carbonate, a phosphate-binding agent designed for hyperphosphatemia in chronic kidney disease patients on dialysis [2][3]. Additionally, the portfolio features UNI-494, an investigational therapy for acute kidney injury [3][4]. UNI-494 has received Orphan Drug Designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [2][3]. The company noted that UNI-494 has completed a Phase 1 dose-ranging safety study in healthy volunteers [3][4].
Recent Regulatory and Market Context
The presentation comes following a Complete Response Letter issued by the FDA on June 30, 2026, regarding manufacturing deficiencies [3]. This regulatory development resulted in a -39.1% share price reaction at the time [3]. Subsequently, the company released Q2 2026 financial results on August 12, 2026, which saw an +8.2% share price reaction despite negative sentiment [3]. Investors will likely seek clarity on the regulatory strategy and path forward during the September 15, 2026 session [1][3].
Event Accessibility and Timing
The presentation is scheduled for Tuesday, September 15, 2026, at 11:00 a.m. ET [2][4]. A live and archived webcast will be accessible via the Investors section of the company’s website [1][2]. As of Wednesday, 2 September 2026, the event remains a future occurrence relative to the announcement date [1][3]. This conference participation represents a key opportunity for the company to engage with the investment community following recent regulatory updates [1][3].